Halozyme Therapeutics, Inc.
HALO
Rang in Aktien
#1547
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San... Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.
Aktienkurs
$123.84
Zuletzt synchronisiert: 2026-10-20
Marktkapitalisierung
$14.06B
Veränderung (1 Tag)
1.09%
Veränderung (1 Jahr)
85.17%
Land
US
Handel Halozyme Therapeutics, Inc. (HALO)
Kategorie
Healthcare
Gewinn für Halozyme Therapeutics, Inc. (HALO)
Gewinn im Jun 2026 TTM: $583.34M
Laut den aktuellen Finanzberichten von Halozyme Therapeutics, Inc. betragen die aktuellen Gewinne des Unternehmens $583.34M. Im Jahr 2023 erzielte das Unternehmen einen Gewinn von $348.33M, eine Steigerung gegenüber dem Gewinn im Jahr 2022, der $248.92M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Halozyme Therapeutics, Inc. von 2001 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $583.34M | 4.70% |
| 2024 | $557.13M | 59.94% |
| 2023 | $348.33M | 39.94% |
| 2022 | $248.92M | 0.16% |
| 2021 | $248.52M | 92.20% |
| 2020 | $129.30M | -278.96% |
| 2019 | $-72.25M | -9.45% |
| 2018 | $-79.79M | -229.51% |
| 2017 | $61.61M | -160.48% |
| 2016 | $-101.86M | 216.03% |
| 2015 | $-32.23M | -52.86% |
| 2014 | $-68.38M | -18.09% |
| 2013 | $-83.48M | 55.88% |
| 2012 | $-53.55M | -99.73% |
| 2011 | $-19.77B | 37,032.30% |
| 2010 | $-53.24M | -8.77% |
| 2009 | $-58.36M | 19.79% |
| 2008 | $-48.72M | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | -100.00% |
| 2005 | $-13.28M | 46.02% |
| 2004 | $-9.09M | 0.00% |
| 2003 | 0.00 | -100.00% |
| 2002 | $-64.46K | 62.57% |
| 2001 | $-39.65K | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| $5.27B | 804.26% |
US
|
|
| $-3.09B | -629.20% |
US
|
|
| $-4.02B | -788.49% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 234.39% |
NL
|
